{"result": "(\"entity\"<|>AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS<|>ORGANIZATION<|>The American Association of Clinical Endocrinologists (AACE) is a professional organization that provides guidelines for the treatment of diabetes and cardiovascular disease management.)\n##\n(\"entity\"<|>DIABETES<|>EVENT<|>Diabetes is a chronic condition that affects how the body processes blood sugar (glucose) and is a focus of the treatment guidelines discussed.)\n##\n(\"entity\"<|>CARVEDILOL<|>ORGANIZATION<|>Carvedilol is a non-selective beta-blocker with alpha-blocking activity and antioxidant effects, used in the treatment of cardiovascular conditions.)\n##\n(\"entity\"<|>GLIFLOZINAS<|>ORGANIZATION<|>Gliflozins are a class of medications used to lower blood sugar levels in patients with diabetes.)\n##\n(\"entity\"<|>W-3 FATTY ACIDS<|>ORGANIZATION<|>W-3 fatty acids are essential fats found in food that are important for heart health and are discussed in the context of cardiovascular disease prevention.)\n##\n(\"relationship\"<|>AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS<|>DIABETES<|>The AACE provides guidelines and recommendations for the management of diabetes and related cardiovascular risks.<|>8)\n##\n(\"relationship\"<|>CARVEDILOL<|>DIABETES<|>Carvedilol is mentioned in the context of improving insulin sensitivity in patients with diabetes.<|>7)\n##\n(\"relationship\"<|>GLIFLOZINAS<|>DIABETES<|>Gliflozins are associated with the management of blood sugar levels in diabetic patients.<|>7)\n##\n(\"relationship\"<|>W-3 FATTY ACIDS<|>DIABETES<|>W-3 fatty acids are discussed as a preventive measure for cardiovascular events in diabetic patients.<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: moderada.\n               sivo (11,3 %) comparado con el grupo convencional (6,1%), el beneficio de menor mortali-\n               dad en el grupo de tratamiento intensivo se mantuvo.                                                                                    B. Medidas sobre el estilo de vida y estatinas de alta intensidad.\n                                                                                                                                                       C. Medidas sobre el estilo de vida únicamente.\n               Referencias:\n               • Gubitosi-Klug RA; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions       D.   Nada de lo anterior.\n                 and complications study at 30 years: summary and future directions. Diabetes Care. 2014;37(1):44-9.\n               • Lachin JM, Orchard TJ, Nathan DM; DCCT/EDIC Research Group. Update on cardiovascular outcomes at 30 years of the diabetes\n                 control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):39-43.      COMENTARIO\n               • Writing Group for the DCCT/EDIC Research Group, Orchard TJ, Nathan DM, Zinman B, Cleary P, Brillon D, Backlund JY, Lachin JM.\n                 Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015;313(1):45-53.\n                                                                                                                                                       Para pacientes de todas las edades con diabetes y enfermedad cardiovascular ateroescle-\n                                                                                                                                                       rótica o riesgo de enfermedad cardiovascular ateroesclerótica de 10 años superior al 20%,\n     2.5 Tratamiento                                                                                                                                   la terapia con estatinas de alta intensidad debe añadirse a los cambios de estilo de vida.\n                                                                                                                                                       Para los pacientes con diabetes de 40 a 75 años y mayores de 75 años sin factores adicio-\n                                                                                                                                                       nales de riesgo cardiovascular, está indicado el uso de estatinas de intensidad moderada\n        55     En el documento sobre el tratamiento de la diabetes que propone la American                                                             además de medidas de estilo de vida.\n               Association of Clinical Endocrinologists (AACE), en su actualización del año 2017,                                                      Para pacientes menores de 40 años con diabetes y factores de riesgo adicionales de enfer-\n               se establecen unos aspectos de estilo de vida que es preciso tener en cuenta con                                                        medad cardiovascular ateroesclerótica, se debe considerar el uso de estatinas de intensi-\n               el objetivo de reducir el riesgo cardiovascular del paciente diabético. Señale aquel                                                    dad moderada además de medidas de estilo de vida.\n               que no se indica en dicho documento:                                                                                                    Referencias:\n                                                                                                                                                       • American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019.\n               A. Actividad física regular.                                                                                                              Diabetes Care. 2019;42(Suppl 1):S103-23.\n               B. Abstención absoluta de la ingesta de bebidas alcohólicas.\n               C. Una suficiente cantidad de horas de sueño.                                                                                           Señale la respuesta correcta:\n               D.   Cese del hábito de fumar y del uso de productos relacionados con el tabaco.                                                    57  A. El carvedilol disminuye la resistencia insulínica y tiene efectos antioxidantes.\n                                                                                                                                                       B. Se recomienda el aporte de un complemento de w-3 para prevenir eventos\n               COMENTARIO                                                                                                                                   cardiovasculares.\n               Los componentes clave de la terapia de estilo de vida incluyen terapia de nutrición médica,                                             C. El uso de gliflozinas se asocia con un descenso de glucagón.\n               actividad física regular, suficientes horas de sueño, apoyo conductual y abandono del hábi-                                             D.   El descenso nocturno de la presión arterial se conserva a pesar de la aparición\n               to de fumar, evitando todos los productos de tabaco.                                                                                         de microalbuminuria.\n\n\n\n116                                                                                                                                                                                                                                                                                     117\n---\n                                                                                                                                                                                                                                         DIABETES                          2\n\n\n\n         COMENTARIO                                                                                                                              cardiovascular, después de una discusión con el paciente sobre los beneficios frente a un\n         El carvedilol es un agente betabloqueante no selectivo con actividad bloqueante α1 y efecto                                             mayor riesgo de sangrado.\n         antioxidante; en dos estudios comparados con este agente y metoprolol o atenolol se com-                                                Referencias:\n         probó una mejoría de la sensibilidad a la insulina tras 3 a 6 meses de tratamiento.                                                     • American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019.\n                                                                                                                                                   Diabetes Care. 2019;42(Suppl 1):S103-23.\n         Los tipos principales de ácidos grasos w-3 son el ácido α-linolénico (ALA), una grasa que\n         se  encuentra en los alimentos              de   origen vegetal,      el ácido eicosapentaenoico (EPA)                y  el\n         ácido docosahexaenoico (DHA), ambos derivados del pescado. El aumento de EPA y DHA                                                  59  Señale la afirmación falsa en relación con los efectos de los fá\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}